GleamWall
中文EN

CLYM Climb Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1768446 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.9%
TTM EPS YoY-37.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.3%
ROA-28.3%
ROIC (approx.)-31.1%
Asset turnover—

Leverage & solvency

Liabilities / assets3.6%
Debt / equity0.00x
Current ratio26.58x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$46.71M$14.34M
SG&A expense$21.17M$16.02M
Operating income-$67.88M-$82.02M
Income tax$0$0
Net income-$59.85M-$73.90M
EBITDA-$67.79M-$82.02M
EPS (basic)-0.88-1.53
EPS (diluted)-0.88-1.53
Weighted avg. shares (diluted)67.81M48.16M
Balance sheet
Cash & equivalents$35.69M$87.23M
Short-term investments$65.39M$63.69M
Current assets$105.85M$154.87M
PP&E, net$288,000$199,000
Total assets$167.74M$217.19M
Current liabilities$6.98M$4.93M
Total liabilities$7.27M$5.31M
Shareholders' equity$160.47M$211.88M
Shares outstanding47.77M67.26M
Cash flow statement
Operating cash flow-$54.36M-$15.56M
Capital expenditure$186,000$0
Free cash flow-$54.54M-$15.56M
Investing cash flow$2.83M-$121.09M
Financing cash flow-$21,000$130.73M
Depreciation & amortization$97,000$0
Stock-based compensation$8.05M$5.56M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.